Observational study on patients with myelofibrosis in Europe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study aims to enroll consecutive patients diagnosed with myelofibrosis according to the 2016 or 2022 WHO criteria from various European hematological centers. The study will collect data from both retrospective and prospective patient visits, with yearly follow-ups scheduled until the end of data collection in 2028. The goal is to describe the clinical epidemiology of myelofibrosis, a rare bone marrow disorder with significant symptom burden and poor prognosis, and to refine diagnostic criteria and treatment recommendations based on evolving knowledge in the field.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027
* Age ≥ 18 years
* Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives

Exclusion Criteria:

* Diagnosis of early/prefibrotic primary myelofibrosis
* Concurrent participation to interventional clinical trials in MF

Where it's running

• Hematology Center after Prof.R.H. Yeolyan
  Yerevan, Armenia Recruiting
• University Medicine Hannover
  Hanover, Germany Recruiting
• University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum
  Minden, Germany Recruiting
• A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia
  Alessandria, Italy Recruiting
• ASST Papa Giovanni XXIII, SC Ematologia
  Bergamo, Italy Recruiting
• Policlinico S. Orsola - Malpighi, Unità di Ematologia
  Bologna, Italy Recruiting

Study contacts

• Study coordinator: Tiziano Barbui, Md
• Email: tbarbui@fondazionefrom.it
• Phone: 0352675134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Nelfinavir to improve anemia in people with myelofibrosis by restoring iron delivery to the bone marrow

  This trial tests whether the antiviral drug nelfinavir can help people with myelofibrosis and anemia by raising hemoglobin and lowering blood markers of fibrosis.

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07281781

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Elritercept vs. placebo for adults with myelofibrosis and anemia on ruxolitinib

  This study tests whether elritercept can improve anemia in adults with myelofibrosis who are taking ruxolitinib, compared with placebo.

  Recruiting at 11 sites Phase 3 Takeda · Gilbert, Arizona and 213 other locations · NCT07623161

• TQ05105 tablets for intermediate/high-risk myelofibrosis

  This phase 2 study tests TQ05105 tablets to see if they help people with intermediate or high-risk myelofibrosis who have not benefited from prior JAK inhibitors.

  Recruiting at 24 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 23 other locations · NCT07551427

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.